Epigenetic Modifications: Therapeutic Potential in Cancer

Detalhes bibliográficos
Autor(a) principal: Sachan,Manisha
Data de Publicação: 2015
Outros Autores: Kaur,Manpreet
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Archives of Biology and Technology
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-89132015000400526
Resumo: Epigenetic modifications and alterations in chromatin structure and function contribute to the cumulative changes observed as normal cells undergo malignant transformation. These modifications and enzymes (DNA methyltransferases, histone deacetylases, histone methyltransferases, and demethylases) related to them have been deeply studied to develop new drugs, epigenome-targeted therapies and new diagnostic tools. Epigenetic modifiers aim to restore normal epigenetic modification patterns through the inhibition of epigenetic modifier enzymes. Four of them (azacitidine, decitabine, vorinostat and romidepsin) are approved by the U.S. Food and Drug Administration. This article provides an overview about the known functional roles of epigenetic enzymes in cancer development.
id TECPAR-1_310336c7a0c4ca7fba16f23dbfb1b3f9
oai_identifier_str oai:scielo:S1516-89132015000400526
network_acronym_str TECPAR-1
network_name_str Brazilian Archives of Biology and Technology
repository_id_str
spelling Epigenetic Modifications: Therapeutic Potential in CancerHDAC inhibitorsCancer epigeneticsHistone modificationEpigenetic modifications and alterations in chromatin structure and function contribute to the cumulative changes observed as normal cells undergo malignant transformation. These modifications and enzymes (DNA methyltransferases, histone deacetylases, histone methyltransferases, and demethylases) related to them have been deeply studied to develop new drugs, epigenome-targeted therapies and new diagnostic tools. Epigenetic modifiers aim to restore normal epigenetic modification patterns through the inhibition of epigenetic modifier enzymes. Four of them (azacitidine, decitabine, vorinostat and romidepsin) are approved by the U.S. Food and Drug Administration. This article provides an overview about the known functional roles of epigenetic enzymes in cancer development.Instituto de Tecnologia do Paraná - Tecpar2015-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-89132015000400526Brazilian Archives of Biology and Technology v.58 n.4 2015reponame:Brazilian Archives of Biology and Technologyinstname:Instituto de Tecnologia do Paraná (Tecpar)instacron:TECPAR10.1590/S1516-8913201500132info:eu-repo/semantics/openAccessSachan,ManishaKaur,Manpreeteng2015-10-26T00:00:00Zoai:scielo:S1516-89132015000400526Revistahttps://www.scielo.br/j/babt/https://old.scielo.br/oai/scielo-oai.phpbabt@tecpar.br||babt@tecpar.br1678-43241516-8913opendoar:2015-10-26T00:00Brazilian Archives of Biology and Technology - Instituto de Tecnologia do Paraná (Tecpar)false
dc.title.none.fl_str_mv Epigenetic Modifications: Therapeutic Potential in Cancer
title Epigenetic Modifications: Therapeutic Potential in Cancer
spellingShingle Epigenetic Modifications: Therapeutic Potential in Cancer
Sachan,Manisha
HDAC inhibitors
Cancer epigenetics
Histone modification
title_short Epigenetic Modifications: Therapeutic Potential in Cancer
title_full Epigenetic Modifications: Therapeutic Potential in Cancer
title_fullStr Epigenetic Modifications: Therapeutic Potential in Cancer
title_full_unstemmed Epigenetic Modifications: Therapeutic Potential in Cancer
title_sort Epigenetic Modifications: Therapeutic Potential in Cancer
author Sachan,Manisha
author_facet Sachan,Manisha
Kaur,Manpreet
author_role author
author2 Kaur,Manpreet
author2_role author
dc.contributor.author.fl_str_mv Sachan,Manisha
Kaur,Manpreet
dc.subject.por.fl_str_mv HDAC inhibitors
Cancer epigenetics
Histone modification
topic HDAC inhibitors
Cancer epigenetics
Histone modification
description Epigenetic modifications and alterations in chromatin structure and function contribute to the cumulative changes observed as normal cells undergo malignant transformation. These modifications and enzymes (DNA methyltransferases, histone deacetylases, histone methyltransferases, and demethylases) related to them have been deeply studied to develop new drugs, epigenome-targeted therapies and new diagnostic tools. Epigenetic modifiers aim to restore normal epigenetic modification patterns through the inhibition of epigenetic modifier enzymes. Four of them (azacitidine, decitabine, vorinostat and romidepsin) are approved by the U.S. Food and Drug Administration. This article provides an overview about the known functional roles of epigenetic enzymes in cancer development.
publishDate 2015
dc.date.none.fl_str_mv 2015-08-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-89132015000400526
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-89132015000400526
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1516-8913201500132
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Instituto de Tecnologia do Paraná - Tecpar
publisher.none.fl_str_mv Instituto de Tecnologia do Paraná - Tecpar
dc.source.none.fl_str_mv Brazilian Archives of Biology and Technology v.58 n.4 2015
reponame:Brazilian Archives of Biology and Technology
instname:Instituto de Tecnologia do Paraná (Tecpar)
instacron:TECPAR
instname_str Instituto de Tecnologia do Paraná (Tecpar)
instacron_str TECPAR
institution TECPAR
reponame_str Brazilian Archives of Biology and Technology
collection Brazilian Archives of Biology and Technology
repository.name.fl_str_mv Brazilian Archives of Biology and Technology - Instituto de Tecnologia do Paraná (Tecpar)
repository.mail.fl_str_mv babt@tecpar.br||babt@tecpar.br
_version_ 1750318276926242816

Registros relacionados